Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAG1 | P54619 | 17/20 | 0.85 |
| ▸ | PRKAB1 | Q9Y478 | 17/20 | 0.85 |
| ▸ | PRKAA2 | P54646 | 15/20 | 0.85 |
| ▸ | PRKAA1 | Q13131 | 7/20 | 0.80 |
| ▸ | PRKAB2 | O43741 | 3/20 | 0.80 |
| ▸ | PRKAG3 | Q9UGI9 | 3/20 | 0.80 |
| ▸ | PRKAG2 | Q9UGJ0 | 3/20 | 0.80 |
| ▸ | TFDP2 | Q14188 | 1/20 | 0.80 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3481079 | 0.94 | PRKAG1 (0.88) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 | |
| SCHEMBL3481391 | 0.92 | PRKAG1 (0.81) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 | |
| SCHEMBL3481343 | 0.90 | PRKAG1 (0.85) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 | |
| SCHEMBL3481453 | 0.89 | PRKAG1 (0.96) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 | |
| SCHEMBL30788331 | 0.89 | PRKAG1 (1.00) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 | |
| SCHEMBL3036566 | 0.89 | PRKAG1 (1.00) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 | |
| SCHEMBL29376061 | 0.89 | PRKAG1 (1.00) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 | |
| SCHEMBL3481985 | 0.87 | PRKAG1 (0.81) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 | |
| SCHEMBL3481166 | 0.87 | PRKAG1 (0.80) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 | |
| SCHEMBL13437301 | 0.87 | PRKAG1 (0.96) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3500558-A1 | BENZIMIDAZOLE DIRECT AMPK ACTIVATORS | Rigel Pharmaceuticals, Inc. (US) | 2019-06-26 | — | — | EP | claimed |
| WO-2018035128-A1 | BENZIMIDAZOLE DIRECT AMPK ACTIVATORS | RIGEL PHARMACEUTICALS, INC. (US) | 2018-02-22 | — | — | WO | claimed |
| US-20180051006-A1 | DIRECT AMPK ACTIVATORS | MIDCAP FINANCIAL TRUST | 2018-02-22 | — | — | US | claimed |
| US-20220098175-A1 | DIRECT AMPK ACTIVATORS | RIGEL PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | US | disclosed |
| US-11174246-B2 | Direct AMPK activators | RIGEL PHARMACEUTICALS, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20180051006-A1 | DIRECT AMPK ACTIVATORS | MIDCAP FINANCIAL TRUST | 2018-02-22 | — | — | US | disclosed |
| US-8394969-B2 | Cyclic benzimidazole derivatives useful as anti-diabetic agents | MERCK SHARP & DOHME CORP. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394969-B2 | Cyclic benzimidazole derivatives useful as anti-diabetic agents | MERCK SHARP & DOHME CORP. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394969-B2 | Cyclic benzimidazole derivatives useful as anti-diabetic agents | MERCK SHARP & DOHME CORP. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20100081643-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME LLC | 2010-04-01 | — | — | US | disclosed |
| US-20100081643-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME LLC | 2010-04-01 | — | — | US | disclosed |
| US-20100081643-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME LLC | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174246-B2 | Direct AMPK activators | PRKAA1, PRKAG1, PRKAB1 | PRKAG1 2/4885PRKAB1 3/4885PRKAA2 5/4885 |
| US-20100081643-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | PRKAG2, PRKAG1, PRKAB2 | PRKAG1 2/4885PRKAB1 5/4885PRKAA2 12/4885 |
| US-20180051006-A1 | DIRECT AMPK ACTIVATORS | PRKAA1, PRKAG1, PRKAB1 | PRKAG1 2/4885PRKAB1 3/4885PRKAA2 5/4885 |
| US-20220098175-A1 | DIRECT AMPK ACTIVATORS | PRKAA1, PRKAG1, PRKAB1 | PRKAG1 2/4885PRKAB1 3/4885PRKAA2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.